|1.||Piert, Morand: 5 articles (10/2011 - 01/2005)|
|2.||Busk, Morten: 4 articles (10/2010 - 03/2008)|
|3.||Jakobsen, Steen: 4 articles (10/2010 - 03/2008)|
|4.||Overgaard, Jens: 4 articles (10/2010 - 03/2008)|
|5.||Bussink, Johan: 4 articles (09/2009 - 03/2008)|
|6.||Beck, Roswitha: 4 articles (04/2008 - 01/2005)|
|7.||Souvatzoglou, Michael: 3 articles (09/2010 - 06/2007)|
|8.||Horsman, Michael R: 3 articles (09/2009 - 03/2008)|
|9.||Machulla, Hans-Jürgen: 3 articles (04/2008 - 01/2005)|
|10.||Wester, Hans-Jürgen: 3 articles (04/2008 - 01/2005)|
03/15/2008 - "The aim of this study was to examine the in vivo hypoxia selectivity of fluoroazomycin arabinoside ([18F]-FAZA), a promising tracer with improved washout kinetics from oxygenated tissue. "
01/01/2013 - "Positron emission tomography (PET) using hypoxia tracers such as fluoroazomycin arabinoside (FAZA) may allow identification of patients with hypoxic tumours and the monitoring of the efficacy of hypoxia-targeting treatment. "
08/01/2013 - "This study evaluated tumoural hypoxia using fluoroazomycin arabinoside ((18) F-FAZA) positron emission tomography (PET) scans among patients with locoregionally advanced NSCLC treated with definitive chemoradiation. "
10/01/2007 - "This study was performed to evaluate the feasibility of use of (18)F-labelled fluoroazomycin arabinoside ([(18)F]FAZA) for clinical PET imaging of tumour hypoxia. "
12/01/2015 - "[(18)F]fluoroazomycin arabinoside (FAZA) positron emission tomography (PET) has been identified as a robust method for quantification of hypoxia both preclinically and clinically. "
01/15/2015 - "18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243."
10/01/2011 - "None of these lesions was found to be positive for CAIX or visualized by 18F-FAZA PET/CT while IHC for HIF-1α showed variable staining of tumor tissues. "
10/01/2011 - "Whole mount histology identified 43 tumor nodules, 19 of them larger than 1 ml as determined on coregistered volumes featuring 18F-FAZA, MRI, and histological 3-D image information. "
09/01/2010 - "Quantitative assessment of hypoxia kinetic models by a cross-study of dynamic 18F-FAZA and 15O-H2O in patients with head and neck tumors."
04/01/2008 - "The study revealed a substantial spatial discordance of the 18F-FAZA and 125I-Gluco-RGD tumor distribution suggesting that hypoxia and angiogenesis are not necessarily spatially linked in malignancies. "
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
09/01/2005 - "In this study, the ability of gefitinib to modulate intratumoral oxygenation was evaluated in human EGFR-expressing A431 squamous cell carcinoma xenografts using in vivo small animal positron emission tomography (PET) imaging with the hypoxia marker [(18)F]fluoroazomycin arabinoside (FAZA) and by the immunohistochemical detection of hypoxia-induced adducts of the 2-nitroimidazole, pimonidazole. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/01/2014 - "Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients."
08/01/2013 - "Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy."
08/01/2013 - "PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients."
12/01/2008 - "Here, we compare the oxygenation-dependent retention of fluoroazomycin arabinoside ([(18)F]FAZA), a promising but not well-characterised hypoxia-specific tracer, and fluorodeoxyglucose ([(18)F]FDG) in four carcinoma cell lines. "
10/01/2010 - "Subcutaneous and orthotopic human A549 lung carcinomas growing in nude mice as well as spontaneous K-ras or Myc-induced lung tumors grown in situ or subcutaneously were studied using fluorodeoxyglucose and fluoroazomycin arabinoside positron emission tomography, and postmortem by immunohistochemical observation of the hypoxia marker pimonidazole. "
|5.||Integrin beta3 (GPIIIa)
|8.||copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)
|9.||tirapazamine (SR 4233)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)